Crossref
FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease
JAMA · 18.08.2026 · 336 (7) · 539
DOI: 10.1001/jama.2026.9488 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 18.08.2026. Verfasst von Samantha Anderer.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
The US Food and Drug Administration (FDA) issued supplemental approval of a gene therapy for patients aged 2 years or older with either sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia.
Zitieren
APA
Anderer, S. (2026). FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease. JAMA, 336(7), 539. https://doi.org/10.1001/jama.2026.9488
Vancouver
Anderer S. FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease. JAMA. 2026;336(7):539. doi:10.1001/jama.2026.9488
BibTeX
@article{Anderer2026,
author = {Anderer, Samantha},
title = {FDA Approves Gene Therapy for Younger Children With Sickle Cell Disease},
journal = {JAMA},
year = {2026},
volume = {336},
number = {7},
pages = {539},
doi = {10.1001/jama.2026.9488}
}
EUVIMED